SA biotech buys Birmingham company

CytoBioscience CEO James Garvin said the acquisition of BioDtech is a big win for his San Antonio-based ...

SA biotech CEO: Company on the verge of taking cancer-detection product to market

Seno Medical Instruments Inc. CEO Tom Umbel said the company is picking up momentum. GABE HERNANDEZ | ...


BioMed SA Annual Breakfast Meeting

When: 7:30-9:30 AM Tuesday, December 18, 2018 Where: Omni Hotel, 9821 Colonnade Blvd. Join ...
Medical Device Firm Innovative Trauma Care Appoints Catherine (Cathy) Burzik to Board of Directors
November 6, 2013

[November 6, 2013- SAN ANTONIO, TEXAS] iTraumaCare, an early-stage medical device firm focused on developing traumatic injury solutions for first responder and military medicine applications, has added Catherine (Cathy) Burzik to its Board of Directors.

Ms. Burzik has successfully led several major medical device, diagnostic, diagnostic imaging and life sciences businesses. Most recently she served as President, Chief Executive Officer and Director of Kinetic Concepts, Inc. (NYSE: KCI), a leading medical device company specializing in the fields of woundcare and regenerative medicine. KCI was taken private by Apax Partners in 2011 for $6.1B (9 X EBIDTA). During her tenure KCI's stock price doubled. Ms. Burzik led significant product innovation, global expansion as well as diversification into regenerative medicine through the $1.7B acquisition of LifeCell. Prior to joining KCI in November 2006, she served as President of Applied Biosystems, the leading life sciences DNA sequencing company. Ms. Burzik has also held senior executive positions at Eastman Kodak and Johnson & Johnson (J&J). She is currently a general partner at Targeted Technologies, as well as a member of the Board of Directors of several companies including Becton-Dickinson and Company (NYSE: BDX); the San Antonio Branch of the Dallas Federal Reserve Board; ViroXis Corporation; and the American College of Wound Healing and Tissue Repair. She has a bachelor's degree in Mathematics from Canisius College in Buffalo, New York, and a master's degree in Mathematics from the University of Buffalo.

iTraumaCare's Executive Chairman of the Board Phil Faris said, "The strength of experience and depth of knowledge that Ms. Burzik brings to our Board will be invaluable as we move the iTClamp toward global adoption."

The iTClamp is designed to control severe bleeding - a leading cause of death in traumatic injury - in seconds. The iTClamp seals the edges of a wound closed to create a temporary pool of blood under pressure, which forms a stable clot that mitigates further blood loss until the wound can be surgically repaired. It is available in the US, Canada, the European Union and the Middle East.

The iTClamp is the first product from iTraumaCare, an emerging medical device firm based in Edmonton, Canada with global commercialization headquarters in San Antonio, Texas. iTraumaCare is addressing unmet needs in the field of emergency medicine by developing, manufacturing, and commercializing solutions to treat common causes of preventable death in traumatic injury scenarios.


Stay informed. Subscribe to BioMed SA news alerts.